Mogrify has developed a systematic big data-science approach (Rackham et al., Nature Genetics, 2016) powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo), needed to convert any mature cell type into any other mature cell type without going through a pluripotent stem cell- or even a progenitor cell-state. The Company will apply this approach to address the issues of efficacy, safety and scalability currently associated with cell therapy development and manufacturing, which is estimated to represent a $30 billion USD market opportunity and is rapidly growing (CAGR +30%).


Mogrify builds on a decade of world-class multidisciplinary science

FANTOM 5 Launch

RIKEN scientists  launch international consortium to provide insight into the regulatory landscape of the transcriptome across as many cell states as possible.


Mogrify Development

Julian Gough and Owen Rackham begin the software development of Mogrify using the unpublished FANTOM 5 consortium data.


Mogrify Validation

Collaboration with Jose Polo to test cell conversions begins and three conversions are validated in just several months.


Foundation Patent

Julian Gough, Owen Rackham, Jose Polo file a PCT patent for the Mogrify V1 algorithm and over 30 direct cell conversions.


Nature Genetics

Mogrify results published in Nature Genetics journal featuring on front page.



Mogrify is incorporated on the 12th of February 2016 by the three academic co-founders: J. Gough, O. Rackham & J. Polo.


Investment & Team

$3.7M seed capital, appoints Dr. Darrin M Disley, OBE as CEO, and launches Mogrify V2 algorithm, hiring up to 18 scientists and raising up to $30M Series A